GE HealthCare and Mayo Clinic announced a novel theranostics study to explore a personalized approach to radioligand therapy for advanced prostate cancer.
Related to this article
The addition of olaparib to radium‐223 did not significantly impact PROs compared with radium‐223 alone in mCRPC with bone metastases.
The top 5 OncLive TV videos of the week cover insights in breast cancer, lymphoma, melanoma, prostate cancer, and ovarian cancer.
The enzalutamide bioequivalent received tentative FDA approval, pending patent expiry on branded Xtandi before final marketing authorization.
Advertisement
Advertisement
Trending on OncLive
1
Dr Ravi on Barriers to PSMA-PET in mHSPC
2
Zanubrutinib Extends TTNT, OS vs Acalabrutinib in Real-World R/R MCL
3
FDA Approves Pegfilgrastim Biosimilar for Non-Myeloid Malignancies
4
GE HealthCare and Mayo Clinic Aim to Advance Personalized Cancer Treatment Through New Theranostics Research Collaboration
5